Mythic Therapeutics
Mythic Therapeutics was a biotech developing antibody-drug conjugates for cancer. Its Phase 1 trial of MYTX-011 was terminated in November 2025 for a business decision, and the company put its assets up for sale, according to ClinicalTrials.gov and BioSpace.
The Story
Mythic Therapeutics was founded in 2017 and based in Waltham, Massachusetts. It developed antibody-drug conjugates (ADCs) using a platform it called FateControl, according to a BioSpace public notice.
Its drug MYTX-011 was studied in a Phase 1 trial in non-small cell lung cancer (ClinicalTrials.gov NCT05652868). The trial enrolled 227 participants.
ClinicalTrials.gov lists the study as terminated, with a completion date of November 7, 2025, and the reason "Business decision."
A BioSpace public notice dated December 2025 said Mythic had executed a general assignment of its assets for liquidation and was seeking a buyer for its intellectual property, including MYTX-011 and the FateControl platform.
Timeline
Funding
Mythic Therapeutics raised $103M+, as reported in the sources below.
What Happened
Wound down in late 2025; its Phase 1 trial was terminated for a business decision, and its assets were put up for sale